Taiho Oncology, Inc.

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or control the disease. About 253 adults will take part in this e…

This study offers ongoing futibatinib treatment to about 15 people with advanced or metastatic cancer who were already benefiting from the drug in a previous study. The main goal is to track long-term safety, including side effects. Participants continue their current dose as lon…

This program gives patients with advanced bile duct cancer (cholangiocarcinoma) that has a specific FGFR2 gene change access to the drug futibatinib. It is for people who have tried standard treatments without success or cannot tolerate them. The goal is to provide treatment when…

This study tests whether adding the experimental drug zipalertinib to standard chemotherapy helps people with a specific type of advanced lung cancer (EGFR exon 20 insertion mutation) live longer without their cancer growing. About 285 adults who have not had prior treatment for …

This study tested a new drug combination (tolinapant plus decitabine/cedazuridine) in 33 adults with a rare and hard-to-treat blood cancer called peripheral T-cell lymphoma that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the comb…

This study offers continued treatment with the drug ASTX727 to adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in earlier studies. The main goal is to gather long-term safety information. About …

This study tests whether adding the drug zipalertinib to standard chemotherapy after lung cancer surgery helps prevent the cancer from returning. It includes 360 adults with early-stage lung cancer (stage IB-IIIA) that has certain uncommon EGFR gene mutations. Participants will r…

This study tests a new combination of drugs (futibatinib plus a PD-1 antibody) in adults with advanced esophageal or pancreatic cancer that cannot be removed by surgery. The goal is to see if the combo shrinks tumors and is safe. About 53 people will take part, and they must not …

This study is testing a combination of two drugs, ASTX727 and venetoclax, in adults with acute myeloid leukemia (AML) who are 75 or older or have health issues that make standard strong chemotherapy too risky. The goal is to see if the combination is safe and effective at control…